{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T17:04:18Z","timestamp":1746119058359},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2003,6]]},"DOI":"10.1007\/s11938-003-0002-0","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T18:10:43Z","timestamp":1180894243000},"page":"201-212","source":"Crossref","is-referenced-by-count":10,"title":["Treatment of extraintestinal manifestations in inflammatory bowel disease"],"prefix":"10.1007","volume":"6","author":[{"given":"Adrian A.","family":"van Bodegraven","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Salvador","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"2_CR1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.7326\/0003-4819-133-10-200011210-00012","volume":"133","author":"CN Bernstein","year":"2000","unstructured":"Bernstein CN, Blanchard JF, Leslie W, et al.: The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000, 133:795\u2013799.","journal-title":"Ann Intern Med"},{"key":"2_CR2","first-page":"2860","volume":"27","author":"K Vlam de","year":"2000","unstructured":"de Vlam K, Mielants H, Cuvelier C, et al.: Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol 2000, 27:2860\u20132865.","journal-title":"J Rheumatol"},{"key":"2_CR3","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1055\/s-0037-1615600","volume":"85","author":"CN Bernstein","year":"2001","unstructured":"Bernstein CN, Blanchard JF, Houston DS, Wajda A: The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001, 85:430\u2013434.","journal-title":"Thromb Haemost"},{"key":"2_CR4","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/003655201317097173","volume":"36","author":"C Salvarani","year":"2001","unstructured":"Salvarani C, Vlachonikolis IG, van der Heijde DM, et al.: Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol 2001, 36:1307\u20131313.","journal-title":"Scand J Gastroenterol"},{"key":"2_CR5","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1572-0241.2001.03756.x","volume":"96","author":"CN Bernstein","year":"2001","unstructured":"Bernstein CN, Blanchard JF, Rawsthorne P, Yu N: The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001, 96:1116\u20131122. First North American population-based study regarding prevalence of extraintestinal manifestations.","journal-title":"Am J Gastroenterol"},{"key":"2_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/aje\/kwf007","volume":"156","author":"P Vestergaard","year":"2002","unstructured":"Vestergaard P, Mosekilde L: Fracture risk in patients with celiac Disease, Crohn\u2019s disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 2002, 156:1\u201310. Study concerning fracture risk in inflammatory bowel disease IBD) patients from the nationwide Danish IBD patient databank (>15,000 patients), showing increased relative risk for bone fractures in Crohn\u2019s disease patients.","journal-title":"Am J Epidemiol"},{"key":"2_CR7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1155\/2001\/612531","volume":"15","author":"G Fornaciari","year":"2001","unstructured":"Fornaciari G, Salvarani C, Beltrami M, et al.: Muscoloskeletal manifestations in inflammatory bowel disease. Can J Gastroenterol 2001, 15:399\u2013403.","journal-title":"Can J Gastroenterol"},{"key":"2_CR8","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0889-8553(21)00215-6","volume":"24","author":"JB Levine","year":"1995","unstructured":"Levine JB, Lukawskitrubish D: Extraintestinal considerations in inflammatory bowel disease. Gastroenterol Clin North Amer 1995, 24:633\u2013646.","journal-title":"Gastroenterol Clin North Amer"},{"key":"2_CR9","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/art.1780391209","volume":"39","author":"D Clegg","year":"1996","unstructured":"Clegg D, Reda D, Weisman M, et al.: Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. Arthtritis Rheum 1996, 39:2004\u20132012.","journal-title":"Arthtritis Rheum"},{"key":"2_CR10","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/art.1780380507","volume":"38","author":"M Dougados","year":"1995","unstructured":"Dougados M, van der Linden S, Leirisalo-Repo M, et al.: Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebocontrolled study. Arthritis Rheum 1995, 38:618\u2013627.","journal-title":"Arthritis Rheum"},{"key":"2_CR11","first-page":"723","volume":"27","author":"BJ Dekker-Saeys","year":"2000","unstructured":"Dekker-Saeys BJ, Dijkmans BA, Tytgat GN: Treatment of spondyloarthropathy with 5-aminosalicylic acid (mesalazine): an open trial. J Rheumatol 2000, 27:723\u2013726.","journal-title":"J Rheumatol"},{"issue":"suppl 3","key":"2_CR12","doi-asserted-by":"crossref","first-page":"iii40","DOI":"10.1136\/ard.61.suppl_3.iii40","volume":"61","author":"M Dougados","year":"2002","unstructured":"Dougados M, Dijkmans B, Khan M, et al.: Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 2002, 61(suppl 3):iii40\u201350.","journal-title":"Ann Rheum Dis"},{"key":"2_CR13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/00002281-199607000-00004","volume":"8","author":"ML Cuellar","year":"1996","unstructured":"Cuellar ML, Espinoza LR: Management of spondyloarthropathies. Curr Opin Rheumatol 1996, 8:288\u2013295.","journal-title":"Curr Opin Rheumatol"},{"key":"2_CR14","doi-asserted-by":"crossref","unstructured":"Garner S, Fidan D, Frankish R, et al.: Celecoxib for rheumatoid arthritis (Cochrane Review). Cochrane Database Syst Rev 2002, CD003831.","DOI":"10.1002\/14651858.CD003831"},{"key":"2_CR15","doi-asserted-by":"crossref","unstructured":"Garner S, Fidan D, Frankish R, et al.: Rofecoxib for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2002, CD003685.","DOI":"10.1002\/14651858.CD003685"},{"issue":"3","key":"2_CR16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/sarh.2002.37215","volume":"32","author":"MC Hochberg","year":"2002","unstructured":"Hochberg MC: New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis. Semin Arthritis Rheum 2002, 32(3 suppl 1):4\u201314.","journal-title":"Semin Arthritis Rheum"},{"key":"2_CR17","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2036.1999.00585.x","volume":"13","author":"SA McCartney","year":"1999","unstructured":"McCartney SA, Mitchell JA, Fairclough PD, et al.: Selective COX-2 inhibitors and human inflammatory bowel disease. Aliment Pharmacol Ther 1999, 13:1115\u20131117.","journal-title":"Aliment Pharmacol Ther"},{"key":"2_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1043-6618(02)00033-6","volume":"46","author":"G Cipolla","year":"2002","unstructured":"Cipolla G, Crema F, Sacco S, et al.: Nonsteroidal antiinflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res 2002, 46:1\u20136. Well-balanced review of effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors on inflamed bowel mucosa.","journal-title":"Pharmacol Res"},{"key":"2_CR19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00002281-199607000-00003","volume":"8","author":"J Braun","year":"1996","unstructured":"Braun J, Sieper J: The sacroiliac joint in the spondyloarthropathies. Curr Opin Rheumatol 1996, 8:275\u2013287.","journal-title":"Curr Opin Rheumatol"},{"issue":"suppl 28","key":"2_CR20","first-page":"S67","volume":"20","author":"IE Horst-Bruinsma van der","year":"2002","unstructured":"van der Horst-Bruinsma IE, Clegg DO, Dijkmans BA: Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs. Clin Exp Rheumatol 2002, 20(6 suppl 28):S67-S70.","journal-title":"Clin Exp Rheumatol"},{"key":"2_CR21","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0140-6736(00)03239-6","volume":"356","author":"F Bosch Van den","year":"2000","unstructured":"Van den Bosch F, Kruithof E, De Vos M, et al.: Crohn\u2019s disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000, 356:1821\u20131822.","journal-title":"Lancet"},{"key":"2_CR22","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1111\/j.1572-0241.2002.06064.x","volume":"97","author":"H Herfarth","year":"2002","unstructured":"Herfarth H, Obermeier F, Andus T, et al.: Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn\u2019s disease. Am J Gastroenterol 2002, 97:2688\u20132690. Data on concomitant beneficial effect of infliximab on Crohn\u2019s disease and joint complaints.","journal-title":"Am J Gastroenterol"},{"key":"2_CR23","first-page":"144","volume":"28","author":"WP Maksymowych","year":"2001","unstructured":"Maksymowych WP, Lambert R, Jhangri GS, et al.: Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol 2001, 28:144\u2013155.","journal-title":"J Rheumatol"},{"key":"2_CR24","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/art.10139","volume":"46","author":"WP Maksymowych","year":"2002","unstructured":"Maksymowych WP, Jhangri GS, Fitzgerald AA, et al.: A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002, 46:766\u2013773. Documents interesting anti-inflammatory therapeutic side effect of pamindronate in axial arthritis, with potential implications for inflammatory bowel disease.","journal-title":"Arthritis Rheum"},{"key":"2_CR25","first-page":"609","volume":"7","author":"H Vogelsang","year":"1995","unstructured":"Vogelsang H, Ferenci P, Resch H, et al.: Prevention of bone mineral loss in patients with Crohn\u2019s disease by long-term oral vitamin D supplementation. Eur J Gastroenterol 1995, 7:609\u2013614.","journal-title":"Eur J Gastroenterol"},{"key":"2_CR26","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/gut.51.5.654","volume":"51","author":"J Klaus","year":"2002","unstructured":"Klaus J, Armbrecht G, Steinkamp M, et al.: High prevalence of osteoporotic vertebral fractures in patients with Crohn\u2019s disease. Gut 2002, 51:654\u2013658. Study shows an alarmingly high rate of bone fracture on vertebral radiograph examination in inflammatory bowel disease patients with osteopenia or osteoporosis, as had been demonstrated by prior DXA measurement.","journal-title":"Gut"},{"key":"2_CR27","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1359\/jbmr.2002.17.8.1349","volume":"17","author":"JH Promislow","year":"2002","unstructured":"Promislow JH, Goodman-Gruen D, Slymen DJ, Barrett- Connor E: Retinol intake and bone mineral density in the elderly: the Rancho Bernardo Study. J Bone Miner Res 2002, 17:1349\u20131358.","journal-title":"J Bone Miner Res"},{"key":"2_CR28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1056\/NEJMoa021171","volume":"348","author":"K Micha\u00eblsson","year":"2003","unstructured":"Micha\u00eblsson K, Lithell H, Vessby B, Melhus H: Serum retinol levels and the risk of fracture. N Engl J Med 2003, 348:287\u2013294.","journal-title":"N Engl J Med"},{"key":"2_CR29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMe020167","volume":"348","author":"P Lips","year":"2003","unstructured":"Lips P: Hypervitaminosis A and fractures [editorial]. N Engl J Med 2003, 348:347\u2013351.","journal-title":"N Engl J Med"},{"key":"2_CR30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0016-5085(98)70362-2","volume":"115","author":"RJ Robinson","year":"1998","unstructured":"Robinson RJ, Krzywicki T, Almond L, et al.: Effect of a low-impact exercise program on bone mineral density in Crohn\u2019s disease: a randomized controlled trial. Gastroenterology 1998, 115:36\u201341.","journal-title":"Gastroenterology"},{"key":"2_CR31","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1053\/gast.2001.29686","volume":"121","author":"P Koutkia","year":"2001","unstructured":"Koutkia P, Lu Z, Chen TC, Holick MF: Treatment of vitamin D deficiency due to Crohn\u2019s disease with tanning bed ultraviolet B radiation. Gastroenterology 2001, 121:1485\u20131488.","journal-title":"Gastroenterology"},{"key":"2_CR32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.1563-2571.2002.02018.x","volume":"29","author":"A Kirchgatterer","year":"2002","unstructured":"Kirchgatterer A, Wenzl HH, Aschl G, et al.: Examination, prevention and treatment of osteoporosis in patients with inflammatory bowel disease: recommendations and reality. Acta Med Austriaca 2002, 29:120\u2013123.","journal-title":"Acta Med Austriaca"},{"key":"2_CR33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1046\/j.1365-2796.1998.00408.x","volume":"244","author":"R Eastell","year":"1998","unstructured":"Eastell R, Reid DM, Compston J, et al.: A UK Consensus Group on mangement of glucocorticoid-induced osteoporosis: an update. J Intern Med 1998, 244:271\u2013292.","journal-title":"J Intern Med"},{"key":"2_CR34","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s002239900334","volume":"61","author":"Y Boutsen","year":"1997","unstructured":"Boutsen Y, Jamart J, Esselinckx W, et al.: Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomzed trial. Calcif Tissue Int 1997, 61:266\u2013271.","journal-title":"Calcif Tissue Int"},{"key":"2_CR35","first-page":"315","volume":"60","author":"AC Heijckmann","year":"2002","unstructured":"Heijckmann AC, Juttmann JR, Wolffenbuttel BH: Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis. Neth J Med 2002, 60:315\u2013319.","journal-title":"Neth J Med"},{"key":"2_CR36","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","volume":"346","author":"IR Reid","year":"2002","unstructured":"Reid IR, Brown JP, Burckhardt P, et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002, 346:653\u2013661.","journal-title":"N Engl J Med"},{"key":"2_CR37","first-page":"274","volume":"8","author":"A Rehberger","year":"1998","unstructured":"Rehberger A, Puspok A, Stallmeister T, et al.: Crohn\u2019s disease masquerading as aphthous ulcers. Eur J Dermatol 1998, 8:274\u2013276.","journal-title":"Eur J Dermatol"},{"key":"2_CR38","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1053\/jhsu.2001.24962","volume":"26","author":"SB Huish","year":"2001","unstructured":"Huish SB, de La Paz EM, Ellis PR, Stern PJ: Pyoderma gangrenosum of the hand: a case series and review of the literature. J Hand Surg 2001, 26:679\u2013685. Article concerns an instructive description of problems in diagnosis and treatment of patients with pyoderma gangrenosum.","journal-title":"J Hand Surg"},{"key":"2_CR39","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/gut.47.3.436","volume":"47","author":"DH Casson","year":"2000","unstructured":"Casson DH, Eltumi M, Tomlin S, et al.: Topical tacrolimus may be effective in the treatment of oral and perineal Crohn\u2019s disease. Gut 2000, 47:436\u2013440.","journal-title":"Gut"},{"key":"2_CR40","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(05)78962-5","volume":"351","author":"HC Schuppe","year":"1998","unstructured":"Schuppe HC, Homey B, Assman T, et al.: Topical treatment for pyoderma gangrenosum. Lancet 1998, 351:831.","journal-title":"Lancet"},{"key":"2_CR41","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1046\/j.1365-2133.1999.02746.x","volume":"140","author":"S Jolles","year":"1999","unstructured":"Jolles S, Niclasse S, Benson A: Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. Br J Dermatol 1999, 140:564\u2013565.","journal-title":"Br J Dermatol"},{"key":"2_CR42","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/00128071-200203020-00005","volume":"3","author":"PR Cohen","year":"2002","unstructured":"Cohen PR, Kurzrock R: Sweet\u2019s syndrome: a review of current treatment options. Am J Clin Dermatol 2002, 3:117\u2013131.","journal-title":"Am J Clin Dermatol"},{"key":"2_CR43","first-page":"A618","volume":"122","author":"E Foster","year":"2002","unstructured":"Foster E, Nguyen KK, Bolce R, Prindiville TP: Cutaneous manifestations of inflammatory bowel disease improve with infliximab therapy [abstract]. Gastroenterology 2002, 122:A618.","journal-title":"Gastroenterology"},{"key":"2_CR44","first-page":"A168","volume":"122","author":"M Reguerio","year":"2002","unstructured":"Reguerio M, Plevy S, Valentine J, et al.: Successful treatment of IBD-associated pyoderma gangrenosum with infliximab [abstract]. Gastroenterology 2002, 122:A168.","journal-title":"Gastroenterology"},{"key":"2_CR45","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0002-9270(00)02325-X","volume":"96","author":"AA Bodegraven van","year":"2001","unstructured":"van Bodegraven AA, Schoorl M, Baak JP, et al.: Hemostatic imbalance in active and quiescent ulcerative colitis. Am J Gastroenterol 2001, 96:487\u2013493.","journal-title":"Am J Gastroenterol"},{"key":"2_CR46","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1572-0241.2003.07160.x","volume":"98","author":"S Saibeni","year":"2003","unstructured":"Saibeni S, Cattaneo M, Vecchi M, et al.: Low vitamin B(6) plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants. Am J Gastroenterol 2003, 98:112\u2013117.","journal-title":"Am J Gastroenterol"},{"key":"2_CR47","first-page":"542","volume":"80","author":"M Cattaneo","year":"1998","unstructured":"Cattaneo M, Vecchi M, Zighetti ML, et al.: High prevalence of hyperchomocysteinemia in patients with inflammatory bowel disease: a pathogenic link with thromboembolic complications? Thromb Haemost 1998, 80:542\u2013545.","journal-title":"Thromb Haemost"},{"key":"2_CR48","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1111\/j.1572-0241.2000.03193.x","volume":"95","author":"B Oldenburg","year":"2000","unstructured":"Oldenburg B, Fijnheer R, van der Griend R, et al.: Homocysteine in inflammatory bowel disease: a risk factor for thromboembolic complications? Am J Gastroenterol 2000, 95:2825\u20132830.","journal-title":"Am J Gastroenterol"},{"key":"2_CR49","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11938-001-0035-1","volume":"4","author":"AA","year":"2001","unstructured":"AA, Dijkmans BA, Lips P, et al.: Extraintestinal complications of inflammatory bowel disease. Curr Treat Option Gastroenterol 2001, 4:227\u2013243.","journal-title":"Curr Treat Option Gastroenterol"},{"key":"2_CR50","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/gut.51.4.536","volume":"51","author":"RA Ransford","year":"2002","unstructured":"Ransford RA, Langman MJ: Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002, 51:536\u2013539.","journal-title":"Gut"},{"key":"2_CR51","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"434","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heyde DM, St Clair EW, et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000, 434:1594\u20131602.","journal-title":"N Engl J Med"},{"key":"2_CR52","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.282.20.1929","volume":"282","author":"MJ Langman","year":"1999","unstructured":"Langman MJ, Jensen DM, Watson DJ, et al.: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999, 282:1929\u20131933.","journal-title":"JAMA"},{"issue":"suppl 8","key":"2_CR53","first-page":"S117","volume":"11","author":"R Goldblum","year":"1993","unstructured":"Goldblum R: Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 1993, 11(suppl 8):S117-S119.","journal-title":"Clin Exp Rheumatol"},{"key":"2_CR54","doi-asserted-by":"crossref","unstructured":"Osiri M, Shea B, Robinson V, et al.: Leflunomide for treating rheumatoid arthritis (Cochrane Review). Cochrane Database Syst Rev 2003, CD002047.","DOI":"10.1002\/14651858.CD002047"},{"key":"2_CR55","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/003655202753416876","volume":"37","author":"J Jahnsen","year":"2002","unstructured":"Jahnsen J, Falch JA, Mowinckel P, Aadland E: Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand J Gastroenterol 2002, 37:192\u2013199.","journal-title":"Scand J Gastroenterol"},{"key":"2_CR56","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1053\/gast.2000.16518","volume":"119","author":"KV Haderslev","year":"2000","unstructured":"Haderslev KV, Tjellesen L, Sorensen HA, Staun M: Alendronate increases lumbar spine bone mineral density in patients with Crohn\u2019s disease. Gastroenterology 2000, 119:639\u2013646.","journal-title":"Gastroenterology"},{"key":"2_CR57","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1365-2362.2003.01103.x","volume":"33","author":"L Rejnmark","year":"2003","unstructured":"Rejnmark L, Vestergaard P, Pedersen AR, et al.: Doseeffect relations of loop- and thiazide-diuretics on calcium homeostasis: a randomized, double-blinded Latin-square multiple cross-over study in postmenopausal osteopenic women. Eur J Clin Invest 2003, 33:41\u201350.","journal-title":"Eur J Clin Invest"},{"key":"2_CR58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0083-6729(02)65059-9","volume":"65","author":"JF Whitfield","year":"2002","unstructured":"Whitfield JF, Morley P, Willick GE: Bone growth stimulators. New tools for treating bone loss and mending fractures. Vitam Horm 2002, 65:1\u201380.","journal-title":"Vitam Horm"},{"key":"2_CR59","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1001\/archinte.162.20.2297","volume":"162","author":"C Crandall","year":"2002","unstructured":"Crandall C: Parathyroid hormone for treatment of osteoporosis. Arch Intern Med 2002, 162:2297\u20132309. Recombinant human parathyroid hormone increases bone mass density more than a potent bisphosphonate, probably due to its different mechanism of action involving osteoblasts.","journal-title":"Arch Intern Med"},{"key":"2_CR60","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1210\/jc.2002-020334","volume":"87","author":"JJ Body","year":"2002","unstructured":"Body JJ, Gaich GA, Scheele WH, et al.: A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002, 87:4528\u20134535.","journal-title":"J Clin Endocrinol Metab"},{"key":"2_CR61","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0092-8674(02)01049-8","volume":"111","author":"S Takeda","year":"2002","unstructured":"Takeda S, Elefteriou F, Levasseur R, et al.: Leptin regulates bone formation via the sympathetic nervous system. Cell 2002, 111:305\u2013317.","journal-title":"Cell"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-003-0002-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-003-0002-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-003-0002-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T14:41:16Z","timestamp":1628952076000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-003-0002-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["2"],"URL":"https:\/\/doi.org\/10.1007\/s11938-003-0002-0","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6]]}}}